Jaguar Health (JAGX) Other Non-Current Liabilities (2014 - 2026)
Jaguar Health's (JAGX) quarterly Other Non-Current Liabilities came in at $187000.0 in Q1 2026, down 99.49% year-on-year from $37.0 million in Q1 2025, and down 99.41% on a QoQ basis from $31.9 million in Q4 2025.
Jaguar Health (JAGX) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Other Non-Current Liabilities data on file, last reported at $187000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 99.49% year-over-year to $187000.0 in Q1 2026; TTM through Mar 2026 was $187000.0, a 99.49% decrease from a year earlier, with the FY2025 full-year figure at $31.9 million, down 9.77% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $187000.0, down from $31.9 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for JAGX reached as high as $37.0 million in Q1 2025 and fell as low as $1000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $24.3 million across 5 years, with a median of $30.9 million in 2023.
- Across the five-year window, Other Non-Current Liabilities surged 783800.0% in 2022 and slumped 99.49% in 2026, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $7.8 million in 2022, then soared by 294.73% to $30.9 million in 2023, then advanced by 14.26% to $35.4 million in 2024, then retreated by 9.77% to $31.9 million in 2025, then sank by 99.41% to $187000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $187000.0 in Q1 2026, $31.9 million in Q4 2025, and $30.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,774.59 Bn | 1,774.53 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.91 Bn | 116.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.79 Bn | 63.04 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - |
| 7 | Argenx Se | 54.75 Bn | 49.57 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.10 Bn | 35.10 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.11 Bn | 36.11 Bn | - |
| 10 | Jaguar Health | 509,443.80 | -9.55 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187,000.00 |
| Dec 31, 2025 | 31.90 Mn |
| Sep 30, 2025 | 30.42 Mn |
| Jun 30, 2025 | 28.81 Mn |
| Mar 31, 2025 | 37.01 Mn |
| Dec 31, 2024 | 35.36 Mn |
| Sep 30, 2024 | 32.79 Mn |
| Mar 31, 2024 | 31.96 Mn |
| Dec 31, 2023 | 30.94 Mn |
| Dec 31, 2022 | 7.84 Mn |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | 7,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 126,000.00 |
| Jun 30, 2020 | 4.09 Mn |
| Mar 31, 2020 | 1.25 Mn |
| Dec 31, 2019 | 1.50 Mn |